Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

RVC study reveals breed dispositions for rare adrenal tumour
Phaeochromocytoma can be life-threatenng for dogs.

Miniature schnauzers among those more likely to receive diagnosis.

The Royal Veterinary College (RVC) has shared new insights into the risk factors of a rare adrenal tumour in dogs.

Researchers analysed health records from dogs with a phaeochromacytoma diagnosis to assess breed disposition, and other risk factors, of the life-threatening condition.

Phaeochromocytoma, which occurs in both dogs and humans, is a rare tumour which develops in the adrenal medulla. It results in the over-production of hormones, including ephinephrine and norephinephrine, due to cardiac complications.

Among the clinical signs are hypertension, collapse, an increased heart rate, and an irregular heart rate. These can be intermittent and can be easily mistaken for hormonal, neurological and cardiovascular conditions.

Diagnostic biochemical tests for the tumour are relatively new to veterinary practices, and there are limited reports of the frequency of the condition.

To improve understanding, researchers analysed RVC VetCompass Programme’s health records for phaeochromocytoma diagnosis in dogs. This included annual prevalence and frequency, as well as the demographic risk factors for the tumour.

The findings revealed an annual incidence risk of 1 per 100,000 dogs – statistics 25 times higher than human phaeochromocytoma.

There were several dog breeds which had a predisposition to the adrenal tumour. This included the soft-coated wheaten terrier (30.9 times more likely), German pointer (11 times more likely), and the miniature schnauzer (4.7 times more likely).

Terrier breeds were identified as having an increased risk of phaeochromocytoma, as were breeds that are predisposed to endocrine tumours.

Other risk factors included being a neutered male and aged between nine and 15 years, with such dogs more likely to receive the diagnosis than entire males and those under the age of nine..

Floryne Buishand, senior lecturer in small animal soft tissue surgery at the RVC, said: “The findings of our study are important for both veterinary and human surgeons and scientists.

“For the first time, we demonstrated that the overall incidence of phaeochromocytoma in dogs is up to 25 times higher compared to the incidence of phaeochromocytoma in humans.

“This underpins the value of spontaneous canine phaeochromocytoma as a translational study model for human phaeochromocytoma because canine phaeochromocytoma samples are more readily available for molecular studies, unlike human phaeochromocytoma samples.” 

The full study can be found in the journal PLoS One

Image © Royal Veterinary College

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.